FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042033090> ?p ?o ?g. }

• W2042033090 endingPage "2987" @default.
• W2042033090 startingPage "2978" @default.
• W2042033090 abstract "Cyclooxygenases regulate the production of prostaglandins and play a role in tumor development and progression. The authors investigated the prognostic impact of expression of the cyclooxygenase (COX) isoforms, COX-1 and COX-2, on disease-free survival and progression-free survival in patients with primary breast carcinoma as well as the association between COX expression and other clinicopathologic parameters.In this study COX isoform expression was determined by immunohistochemistry in a cohort of 221 patients with primary breast carcinoma.Expression of COX-2 was detected in 36% of breast carcinoma samples and was associated significantly with several clinicopathologic parameters, including positive lymph node status (P < 0.0005), larger tumor size (P < 0.0005), poor differentiation (P < 0.0005), vascular invasion (P = 0.03), and negative estrogen receptor status (P = 0.04). In contrast, COX-1 was expressed in 45% of tumors and was associated with smaller tumor size (P = 0.02) and with negative lymph node status (P = 0.01). In a univariate survival analysis, a significant association was observed between elevated COX-2 expression and decreases in disease-free survival (P = 0.0007) and overall survival (P = 0.02). In a multivariate analysis, expression of COX-2 was of borderline significance for disease-free survival (relative risk, 1.90; 95% confidence interval, 1.00-3.59), adjusting for tumor size, histologic grade, number of positive lymph nodes, and patient age. Elevated expression of COX-1 in tumor tissue had no statistically significant influence on patient prognosis.The current data suggest that increased expression of COX-2 may play a role in the progression of primary breast carcinoma. It remains to be investigated whether treatment with selective inhibitors of COX-2 may be an additional therapeutic option for patients with breast carcinoma." @default.
• W2042033090 created "2016-06-24" @default.
• W2042033090 creator A5008098115 @default.
• W2042033090 creator A5016995466 @default.
• W2042033090 creator A5017462100 @default.
• W2042033090 creator A5018744564 @default.
• W2042033090 creator A5033698551 @default.
• W2042033090 creator A5051267900 @default.
• W2042033090 creator A5052500467 @default.
• W2042033090 creator A5066227147 @default.
• W2042033090 creator A5073557455 @default.
• W2042033090 creator A5085663844 @default.
• W2042033090 creator A5086449500 @default.
• W2042033090 date "2003-05-29" @default.
• W2042033090 modified "2023-10-14" @default.
• W2042033090 title "Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma" @default.
• W2042033090 cites W196157878 @default.
• W2042033090 cites W1994209871 @default.
• W2042033090 cites W2010871781 @default.
• W2042033090 cites W2042691743 @default.
• W2042033090 cites W2044573147 @default.
• W2042033090 cites W2050310941 @default.
• W2042033090 cites W2053071688 @default.
• W2042033090 cites W2058526541 @default.
• W2042033090 cites W2100629056 @default.
• W2042033090 cites W2116168419 @default.
• W2042033090 cites W2150966393 @default.
• W2042033090 cites W2169532459 @default.
• W2042033090 doi "https://doi.org/10.1002/cncr.11437" @default.
• W2042033090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12784332" @default.
• W2042033090 hasPublicationYear "2003" @default.
• W2042033090 type Work @default.
• W2042033090 sameAs 2042033090 @default.
• W2042033090 citedByCount "226" @default.
• W2042033090 countsByYear W20420330902012 @default.
• W2042033090 countsByYear W20420330902013 @default.
• W2042033090 countsByYear W20420330902014 @default.
• W2042033090 countsByYear W20420330902015 @default.
• W2042033090 countsByYear W20420330902016 @default.
• W2042033090 countsByYear W20420330902017 @default.
• W2042033090 countsByYear W20420330902018 @default.
• W2042033090 countsByYear W20420330902019 @default.
• W2042033090 countsByYear W20420330902020 @default.
• W2042033090 countsByYear W20420330902021 @default.
• W2042033090 countsByYear W20420330902022 @default.
• W2042033090 countsByYear W20420330902023 @default.
• W2042033090 crossrefType "journal-article" @default.
• W2042033090 hasAuthorship W2042033090A5008098115 @default.
• W2042033090 hasAuthorship W2042033090A5016995466 @default.
• W2042033090 hasAuthorship W2042033090A5017462100 @default.
• W2042033090 hasAuthorship W2042033090A5018744564 @default.
• W2042033090 hasAuthorship W2042033090A5033698551 @default.
• W2042033090 hasAuthorship W2042033090A5051267900 @default.
• W2042033090 hasAuthorship W2042033090A5052500467 @default.
• W2042033090 hasAuthorship W2042033090A5066227147 @default.
• W2042033090 hasAuthorship W2042033090A5073557455 @default.
• W2042033090 hasAuthorship W2042033090A5085663844 @default.
• W2042033090 hasAuthorship W2042033090A5086449500 @default.
• W2042033090 hasBestOaLocation W20420330901 @default.
• W2042033090 hasConcept C10515644 @default.
• W2042033090 hasConcept C121608353 @default.
• W2042033090 hasConcept C126322002 @default.
• W2042033090 hasConcept C142724271 @default.
• W2042033090 hasConcept C143998085 @default.
• W2042033090 hasConcept C144301174 @default.
• W2042033090 hasConcept C181199279 @default.
• W2042033090 hasConcept C204232928 @default.
• W2042033090 hasConcept C2777546739 @default.
• W2042033090 hasConcept C2778001805 @default.
• W2042033090 hasConcept C2779689624 @default.
• W2042033090 hasConcept C2780849966 @default.
• W2042033090 hasConcept C3018521938 @default.
• W2042033090 hasConcept C38180746 @default.
• W2042033090 hasConcept C50382708 @default.
• W2042033090 hasConcept C530470458 @default.
• W2042033090 hasConcept C55493867 @default.
• W2042033090 hasConcept C71924100 @default.
• W2042033090 hasConcept C86803240 @default.
• W2042033090 hasConceptScore W2042033090C10515644 @default.
• W2042033090 hasConceptScore W2042033090C121608353 @default.
• W2042033090 hasConceptScore W2042033090C126322002 @default.
• W2042033090 hasConceptScore W2042033090C142724271 @default.
• W2042033090 hasConceptScore W2042033090C143998085 @default.
• W2042033090 hasConceptScore W2042033090C144301174 @default.
• W2042033090 hasConceptScore W2042033090C181199279 @default.
• W2042033090 hasConceptScore W2042033090C204232928 @default.
• W2042033090 hasConceptScore W2042033090C2777546739 @default.
• W2042033090 hasConceptScore W2042033090C2778001805 @default.
• W2042033090 hasConceptScore W2042033090C2779689624 @default.
• W2042033090 hasConceptScore W2042033090C2780849966 @default.
• W2042033090 hasConceptScore W2042033090C3018521938 @default.
• W2042033090 hasConceptScore W2042033090C38180746 @default.
• W2042033090 hasConceptScore W2042033090C50382708 @default.
• W2042033090 hasConceptScore W2042033090C530470458 @default.
• W2042033090 hasConceptScore W2042033090C55493867 @default.
• W2042033090 hasConceptScore W2042033090C71924100 @default.
• W2042033090 hasConceptScore W2042033090C86803240 @default.
• W2042033090 hasIssue "12" @default.

• next